BioLineRx Ltd. In-Licenses BL-7050, a Novel, Orally-Available Molecule for the Treatment of Neuropathic and Inflammatory Pain

Published: Sep 07, 2011

JERUSALEM--(BUSINESS WIRE)--BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain. Financial terms of the license were not disclosed.

Back to news